IN8bio rises on positive data in treatment trial of blood cancers

IN8bio

12/12/2022 14:52

** Shares of IN8bio Inc  INAB.O  up 5.5% at $2.5
    ** The drug developer reports updated positive data from
ongoing early-stage trial of cell therapy INB-100 in treating
blood cancers 
    ** INB-100 continues to demonstrate a manageable safety
profile with no dose-limiting toxicity and patients in the trial
remained progression-free - INAB
    ** Co says enrollment for second cohort has been initiated
and expects to post additional clinical updates in Q2 of 2023
    ** Including session's gains, stock down 43.3% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))